Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase (vol 8, pg 762, 2020)

被引：1
|
作者：
Pivonello, R.
Fleseriu, M.
Newell-Price, J.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2020年 / 8卷 / 09期
关键词：
D O I：
10.1016/S2213-8587(20)30275-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e4 / e4
页数：1
相关论文
共 50 条
  • [21] Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
    Simuni, Tanya
    Kieburtz, Karl
    Tilley, Barbara
    Elm, Jordan J.
    Ravina, Bernard
    Babcock, Debra
    Emborg, Marina
    Hauser, Robert
    Kamp, Cornelia
    Morgan, John C.
    Ross, G. Webster
    Simon, David K.
    Bainbridge, Jacci
    Baker, Liana
    Bodis-Wollner, Ivan
    Boyd, James
    Cambi, Franca
    Carter, Julie
    Chou, Kelvin
    Dahodwala, Nabila
    Dewey, Richard B., Jr.
    Dhall, Rohit
    Fang, John
    Farrow, Buff
    Feigin, Andrew
    Glazman, Sofya
    Goudreau, John
    LeBlanc, Pauline
    Lee, Stephen
    Leehey, Maureen
    Lew, Mark F.
    Lowenhaupt, Stephanie
    Luo, Sheng
    Pahwa, Rajesh
    Perez, Adriana
    Schneider, Jay
    Scott, Burton
    Shah, Binit
    Shannon, Kathleen M.
    Sharma, Saloni
    Singer, Carlos
    Truong, Daniel
    Wagner, Renee
    Williams, Karen
    Wills, Anne Marie
    Wong, Pei Shieen
    Zadikoff, Cindy
    Zweig, Richard
    LANCET NEUROLOGY, 2015, 14 (08): : 795 - 803
  • [22] The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: A phase III, randomised, double-blind multicentre study
    Chen, Songfeng
    Liu, Deliang
    Chen, Honghui
    Liao, Aijun
    Li, Fangfang
    Liu, Chengxia
    Li, Xing
    Li, Shengbao
    Zhang, Yan
    Wang, Yang
    Xia, Min
    Guo, Qinghong
    Miao, Xinpu
    Wen, Zhili
    Xu, Min
    Yin, Hekun
    Chen, Huixin
    Chen, Minhu
    Xiao, Yinglian
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (12) : 1524 - 1533
  • [23] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietzeet, I
    LANCET NEUROLOGY, 2022, 21 (03):
  • [24] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietze, I
    LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
  • [25] Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised double-blind, multicentre, placebo-controlled phase 3 trial
    Habib, Ali A.
    Zhao, Chongbo
    Aban, Inmaculada
    Franca Jr, Marcondes Cavalcante
    Jose, Jorge Gustavo
    Hoerste, Gerd Meyer zu
    Klimiec-Moskal, Elzbieta
    Pulley, Michael T.
    Tavolini, Dario
    Krumova, Petranka
    Lennon-Chrimes, Sian
    Smith, Jillian
    Thanei, Gian-Andrea
    Blondeau, Kathleen
    Vodopivec, Ivana
    Wolfe, Gil, I
    Murai, Hiroyuki
    LANCET NEUROLOGY, 2025, 24 (02): : 117 - 127
  • [26] Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Di Lorenzo, Carlo
    Khlevner, Julie
    Rodriguez-Araujo, Gerardo
    Xie, Wangang
    Huh, Susanna Y.
    Ando, Masakazu
    Hyams, Jeffrey S.
    Nurko, Samuel
    Benninga, Marc A.
    Simon, Michael
    Hewson, Marcella E.
    Saps, Miguel
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (03): : 238 - 250
  • [27] Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study
    Papp, K.
    Bissonnette, R.
    Rosoph, L.
    Wasel, N.
    Lynde, C. W.
    Searles, G.
    Shear, N. H.
    Huizinga, R. B.
    Maksymowych, W. P.
    LANCET, 2008, 371 (9621): : 1337 - 1342
  • [28] Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial (vol 401, pg 1518, 2023)
    McInnes, Iain B.
    Merola, Joseph F.
    LANCET, 2023, 401 (10392): : 1928 - 1928
  • [29] Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial
    Misawa, Sonoko
    Kuwabara, Satoshi
    Sato, Yasunori
    Yamaguchi, Nobuko
    Nagashima, Kengo
    Katayama, Kanako
    Sekiguchi, Yukari
    Iwai, Yuta
    Amino, Hiroshi
    Suichi, Tomoki
    Yokota, Takanori
    Nishida, Yoichiro
    Kanouchi, Tadashi
    Kohara, Nobuo
    Kawamoto, Michi
    Ishii, Junko
    Kuwahara, Motoi
    Suzuki, Hidekazu
    Hirata, Koichi
    Kokubun, Norito
    Masuda, Ray
    Kaneko, Juntaro
    Yabe, Ichiro
    Sasaki, Hidenao
    Kaida, Ken-ichi
    Takazaki, Hiroshi
    Suzuki, Norihiro
    Suzuki, Shigeaki
    Nodera, Hiroyuki
    Matsui, Naoko
    Tsuji, Shoji
    Koike, Haruki
    Yamasaki, Ryo
    Kusunoki, Susumu
    LANCET NEUROLOGY, 2018, 17 (06): : 519 - 529
  • [30] Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)
    Shimatsu, Akira
    Biller, Beverly M. K.
    Fleseriu, Maria
    Pivonello, Rosario
    Lee, Eun Jig
    Leelawattana, Rattana
    Kim, Jung Hee
    Walia, Rama
    Yu, Yerong
    Liao, Zhihong
    Piacentini, Andrea
    Pedroncelli, Alberto M.
    Snyder, Peter J.
    ENDOCRINE JOURNAL, 2024, 71 (12) : 1103 - 1123
12345